arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Pacira BioSciences, Inc.

PCRX
$24.98 ▼ -0.60 (-2.35%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Neutral
auto_awesome

Analytical Summary

Pacira BioSciences, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.0B
Dividend Yield
Revenue Growth 5.0%
Op. Margin 3.9%
ROIC 0.4%
FCF / Share $0.57
Trailing P/E 356.9x
Price / Book 1.5x
FCF Yield 2.3%
Debt / Equity 0.56
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$177.38M
↑ +5.0%
Net Income Profit after all expenses
$2.92M
↓ -39.4%
Operating Margin Operating profit as % of sales
3.9%
↑ +227.4% 36th
FCF / Share Free cash flow per share
$0.57
↓ -2.4%
Long-Term Debt Long-term obligations
$367.66M
↓ -1.2%

Health Breakdown

Profitability
50
Returns
46
Financial Health
52
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters